Department of Human Services and Health

The rise of #Robodebt: how Twitter activists pushed a government scandal from hashtags to a royal commission

Retrieved on: 
Friday, July 7, 2023
Department of Human Services and Health, Pressure, Tax, Royal Commission into the Robodebt Scheme, Policy, Light, Robodebt scheme, Time, Boxing, Labour, Social media, Department of Human Services, Cryptocurrency, Retail, Centrelink

On the final day of public hearings, Commissioner Catherine Holmes highlighted the crucial role of citizen journalists and activists on Twitter.

Key Points: 
  • On the final day of public hearings, Commissioner Catherine Holmes highlighted the crucial role of citizen journalists and activists on Twitter.
  • As Twitter declines under Elon Musk’s ownership, the #Robodebt saga is a useful reminder of the platform’s potential for social good.

The beginnings

    • The algorithm was faulty and unlawful, resulting in the automatic issuing of thousands of incorrect debt letters, some demanding four- and five-figure sums of money.
    • Vulnerable people reported stories of mental and financial hardship, of long Centrelink call centre queues, and of deep confusion about these debt notices.
    • In late 2016, they also introduced the “robodebt” moniker, which eventually became the official title of the royal commission.

The evolution

    • About 100 Twitter accounts initially produced around 50% of the posts, garnering engagement from some 10,000 others.
    • Much of this early activity was dominated by the #NotMyDebt hashtag, but in 2017 #Robodebt gradually took over.
    • By late 2018, #Robodebt was well established – and overlapped considerably with Australia’s perennial hashtag for political discussion, #auspol.
    • Some prominent Labor politicians (Bill Shorten, Anthony Albanese, Mark Dreyfus) also became active during this early timeframe.

The future

    • Its detrimental impact on thousands of lives has been documented by the royal commission’s hearings.
    • As Commissioner Holmes has acknowledged, Australians have benefited from the unpaid public service of these activists.
    • None of the other major social media platforms provide the same opportunities for highly public engagement.

Longhorn Vaccines & Diagnostics Recognized as BioTech Breakthrough’s “Diagnostics Company of the Year”

Retrieved on: 
Thursday, November 3, 2022
Health, Medical Devices, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Public health, United States Department of Agriculture, RNA, Severe acute respiratory syndrome coronavirus 2, Leadership, DNA, Government, Animal, Pandemic, NA, LLC, Department of Biotechnology, Biopharma LLC, Food, Tuberculosis, Temperature, Biotechnology, RSV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Solution, Monkeypox, Human, Department of Human Services and Health, FDA, HA, Health care, Health, TB, Epitope, Therapy, Vaccine, COVID-19, Collection, Peptide, Infection, Avian influenza, African swine fever virus, Laboratory, Mycobacterium tuberculosis, Program, MTM, Fine chemical, Avian, Longhorn, Genomics, Diagnosis

Longhorn Vaccines & Diagnostics , a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced it has been named Diagnostics Company of the Year in the second annual BioTech Breakthrough Awards program.

Key Points: 
  • Longhorn Vaccines & Diagnostics , a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced it has been named Diagnostics Company of the Year in the second annual BioTech Breakthrough Awards program.
  • Our goal is to improve the delivery of molecular diagnostics to serve critical unmet needs in both the developed and developing world, said Longhorn Vaccines and Diagnostics President Jeff Fischer.
  • We offer a heartfelt congratulations on being our choice for Diagnostics Company of the Year!
  • Longhorn Vaccines and Diagnostics LLC is a One Health and One World company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics.

Centrelink debt recovery system

Retrieved on: 
Monday, October 31, 2022
Government agency, Department of Human Services and Health, Prejudice, Privacy Commissioner, DHS, Department of Human Services, The Department, Privacy Act 1988, Privacy, Commissioner, Australian Federal Police, International Safe Harbor Privacy Principles, Government, Department, Commonwealth, APP, Australian Privacy Commissioner, Disclosure, Financial services, Audit, Internet service provider, Private investigator, Mail order, Centrelink

Centrelink debt recovery system

Key Points: 
  • Centrelink debt recovery system
    Concluding statement Centrelink release of personal information
    29 May 2018
    On 28 February 2017, the former Australian Information Commissioner and Privacy Commissioner announced he had commenced inquiries with the Department of Human Services in response to media reports that Centrelink had released personal information into the public domain.
  • Updated statement Centrelink release of personal information
    16 March 2017
    On February 28, the Australian Privacy Commissioner announced he had commenced inquiries with the Department of Human Services regarding a release of personal information into the public domain.
  • Centrelink release of personal information into the public domain
    28 February 2017
    Statement by the Australian Information and Privacy Commissioner, Timothy Pilgrim
    I am aware of the media reports concerning this issue.
  • Centrelink debt recovery system
    6 January 2017
    Statement by the Australian Information and Privacy Commissioner, Timothy Pilgrim
    My office has been in contact with the Department of Human Services (DHS) and the Office of the Commonwealth Ombudsman about this issue.

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022
Department, Financial compensation, FDA, CF, Mutation, Science, University of Chicago, Patient, Savannah State University Office of Graduate Studies and Sponsored Research, Kidney, CEO, Massachusetts Institute of Technology, United States Attorney General, GLOBE, Â, European Commission, CFA, Degenerative disease, Cancer, Initial public offering, RMAS, Eukaryotic ribosome, MBA, Department of Human Services and Health, Fast Track, Orphan, Humanitarian use licenses, Food, Autosome, BS, Royal commission, Roivant Sciences, RNA, Psoriasis, Polycystic kidney disease, University, Cystic fibrosis, Acquisition, JD, Regulation of tobacco by the U.S. Food and Drug Administration, Overactive bladder, NASDAQ, Uterine fibroid, Management, Pharmaceutical industry

WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

Key Points: 
  • Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board.
  • Following these changes, Eloxxs board is now comprised of five directors.
  • I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations.
  • I am excited to join the board of Eloxx and to contribute to the companys work in developing therapies for rare diseases, said Ms. Androski.

Geneoscopy Announces Formation of Scientific Advisory Board to Inform Strategy for the Advancement of Gastrointestinal Health

Retrieved on: 
Tuesday, June 21, 2022
Digestive, Internal medicine, MACP, RNA, Department, Stanford University School of Medicine, Department of Human Services and Health, MBA, University of Michigan, GI, University School, Technology, National Institute of Diabetes and Digestive and Kidney Diseases, Head, Gastrointestinal cancer, Population health, Nuffield Department of Population Health, Survival, Company, Coronavirus Scientific Advisory Board (Turkey), Genetics, Colorectal cancer, Division, Statistics, Hepatology, Serna, Disease, Large intestine, FACS, Kidney, University, Department of Medicine – University of Pamplona, SAB, Health, Patient, Board, MPH, Diagnosis, Gastrointestinal disease, NIH, New York University Grossman School of Medicine, Medical device, Management, Fast food, Pharmaceutical industry, Medicine, Gastroenterology

ST. LOUIS, June 21, 2022 /PRNewswire/ -- Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in gastroenterology, oncology, and internal medicine. The SAB will provide strategic input based on their scientific knowledge and clinical expertise to help guide Geneoscopy through the development, regulatory and commercial phases for their RNA-based technology to improve GI health, starting with colorectal cancer.

Key Points: 
  • John Carethers, M.D., MACP Professor and Chair, Department of Internal Medicine and Professor, Department of Human Genetics at University of Michigan
    Uri Ladabaum, M.D.
  • The advancement of new technologies is critical for the early detection, diagnosis and potentially even prevention of these illnesses," noted Board member David Lieberman, M.D.
  • "The establishment of our Scientific Advisory Board is a significant step forward in our mission to transform GI health.
  • Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health.